Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert


Search Title by author or title

Primary chemotherapy as the emerging management paradigm for diffuse ocular surface squamous neoplasia (OSSN)

Poster Details

First Author: C.Malhotra INDIA

Co Author(s):    D. Dhingra   A. Jain                 

Abstract Details


To photographically document the variable clinical response of 2 cases of diffuse OSSN to primary chemotherapy with Mitomycin C and to highlight the need for use of more than one chemotherapeutic agents in unresponsive cases.


Cornea Services of the Advanced Eye Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India


Two cases of diffuse OSSN (defined as limbal lesions with greater than 5 clock hours of conjunctival and corneal involvement or by extensive central/ paracentral corneal spread) were treated with 3 cycles of topical mitomycin C 0.04%, instilled 4 times/day.One cycle consisted of one week of instillation of MMC (On week) 1 week of no MMC instillation (off week). Lack of clinical response to 3 cycles, which was seen in the second patient was considered as treatment failure and the patient was switched to treatment with topical and subconjunctival interferon �Î�±2�Î�². The clinical course of both patients was documented photographically.


Case 1, a 76 year old male had OSSN left eye involving 2 clock hours of the temporal limbus and almost the entire cornea. He responded completely to 3 cycles of Mitomycin C, which was serially documented on confocal microscopy and anterior segment optical coherence tomography. Case 2, a 45 year female had diffuse OSSN involving five clock hours of limbus and extending upto the pupil. Lack of response to MMC, necessitated the combined use of weekly subconjunctival (3milion IU/0.5ml) and daily topical interferon �Î�±2�Î�² (1 million IU/ml 4 times/day) following which complete resolution was seen over 3months.


Chemotherapy is fast replacing surgery as the primary modality for treatment of OSSN, especially for diffuse lesions.Though effective in a large majority of cases, variabililty of response to different chemotherapeutic agents is not uncommon as is documented by the above 2 cases. Addition or switch over to another drug is often successful in eliciting the desired response. Interferon �Î�±2�Î�² because of its favourable safety profile is especially useful as a �â�€�˜rescue therapy�â�€�™ in such cases.

Financial Disclosure:


Back to Poster listing